Michael Method
Overview
Explore the profile of Michael Method including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, et al.
Future Oncol
. 2025 Feb;
21(7):807-813.
PMID: 39911057
Selinexor is an investigational, selective oral XPO1 inhibitor that may inhibit myelofibrosis (MF)-relevant JAK/STAT and non-JAK/STAT pathways with potential synergy with ruxolitinib. SENTRY (XPORT-MF-034; NCT04562389) is a Phase 1/3 study...
2.
Moore K, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, et al.
Gynecol Oncol
. 2024 Oct;
191:249-258.
PMID: 39461270
Objective: Mirvetuximab soravtansine-gynx (MIRV) is a novel antibody-drug conjugate targeting folate receptor alpha (FRα), which is overexpressed in epithelial ovarian cancer (EOC), with limited expression on normal tissues. This integrated...
3.
Tu Y, Lagraauw H, Method M, Wang Y, Hanze E, Li L, et al.
Br J Clin Pharmacol
. 2024 Sep;
91(1):220-231.
PMID: 39307840
Aims: This study aimed to investigate exposure-response (ER) relationships in efficacy and safety for mirvetuximab soravtansine (MIRV) which is a first-in-class antibody-drug conjugate approved for the treatment of folate receptor-α-positive...
4.
Coleman R, Lorusso D, Oaknin A, Cecere S, Denys H, Colombo N, et al.
Int J Gynecol Cancer
. 2024 Jun;
34(8):1119-1125.
PMID: 38858103
Objective: The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer (n=105 (efficacy-evaluable)) met its primary endpoint with an objective response rate...
5.
Richardson D, Moore K, Vergote I, Gilbert L, Martin L, Mantia-Smaldone G, et al.
Gynecol Oncol
. 2024 Mar;
185:186-193.
PMID: 38447347
Objective: Evaluate the antitumor activity and safety profile of the triplet combination of mirvetuximab soravtansine (MIRV), carboplatin, and bevacizumab in recurrent, platinum-sensitive ovarian cancer. Methods: Participants with recurrent, platinum-sensitive epithelial...
6.
Moore K, Angelergues A, Konecny G, Garcia Y, Banerjee S, Lorusso D, et al.
N Engl J Med
. 2023 Dec;
389(23):2162-2174.
PMID: 38055253
Background: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States. Methods: We conducted a...
7.
Tu Y, Hanze E, Zhu F, Lagraauw H, Sloss C, Method M, et al.
Br J Clin Pharmacol
. 2023 Oct;
90(2):568-581.
PMID: 37872122
Aims: Mirvetuximab soravtansine is a first-in-class antibody-drug conjugate recently approved for the treatment of folate receptor-α positive ovarian cancer. The aim of this study was to develop a population pharmacokinetic...
8.
Matulonis U, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al.
J Clin Oncol
. 2023 Aug;
41(29):4705-4706.
PMID: 37535884
No abstract available.
9.
Gilbert L, Oaknin A, Matulonis U, Mantia-Smaldone G, Lim P, Castro C, et al.
Gynecol Oncol
. 2023 Feb;
170:241-247.
PMID: 36736157
Purpose: Evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum-resistant ovarian cancer. Methods: Patients with recurrent epithelial ovarian, fallopian tube,...
10.
Matulonis U, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al.
J Clin Oncol
. 2023 Jan;
41(13):2436-2445.
PMID: 36716407
Purpose: Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA...